Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ELOX

Eloxx Pharmaceuticals

ELOX Rare disease Lead: Phase 2 4 Biotech Distilled articles ↓ 19 filings & releases ↓ Cash $62.0M (Jun 30, 2026) ↓ 4 verdicts ↓ 1 timing quote ↓
DermatologyRenal Small Molecule

Market cap $50.2M 4.0M shares (10-Q, Aug 7, 2026) × $12.44 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Exaluren nmADPKD enrollment done2027Exaluren nmADPKD enrollment done, 2027, routine
  2. Exaluren NMAS toplinemid-2027Exaluren NMAS topline, mid-2027, thesis-defining
  3. Exaluren NMAS toplineby mid-2027Exaluren NMAS topline, by mid-2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$62.0M cash and cash equivalents · Jun 30, 2026 (S-1)
Operating cash flow
−$4.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (S-1)
As stated in coverage
$62.0M cash, runway mid-2028 per the update of Oct 20, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Eloxx Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-18 Watch Eloxx Pharmaceuticals (ELOX) — Scientific Deep Dive for Exaluren and the Ribosomal Readthrough Pipeline Interesting biology and a newly-solvent balance sheet, but the entire human efficacy case is three patients on an unvalidated surrogate, the readthrough mechanism class is under an FDA/EMA cloud, and the only meaningful catalyst is a year away after a 230% relisting squeeze.
  2. 2026-08-12 Watch UPDATE: Eloxx Pharmaceuticals (ELOX) - The Quarter Where the Money Showed Up and the Trial Didn't Solvency risk is retired and runway now plausibly covers both 2027 readouts, but the entire efficacy case remains three patients on an unvalidated surrogate with no new human data.
  3. 2026-09-11 Watch UPDATE: Eloxx Pharmaceuticals (ELOX) - The Trial Starts, and So Does the Exit Door First patients dosed in EXACT retires execution risk but the S-1 converts the warrant overhang into registered sellable stock, and the efficacy case remains n=3 on a surrogate no regulator has validated.
  4. 2026-10-20 Watch UPDATE: Eloxx Pharmaceuticals (ELOX) - A Better Endpoint, a Later Date, and a Novartis CMO ADPKD program gains a more credible regulatory endpoint (htTKV) and a seasoned CMO, but its readout slipped to 1H 2029 past the funded runway, and the lead Alport asset's efficacy case is still n=3 on an unvalidated surrogate.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (19)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)